BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical resistance to TKI therapy in CML is a significant problem and is classified as acquired resistance (increasing BCR-ABL1 transcript levels following a substantial decrease) or primary resistance (lack of an adequate initial response).